Consequently, we observed a reduction in CD4+ T-cell frequencies in the cervical lymph nodes of the MSN-MOG-Ce-treated group at the late phase of MS (Fig. 6p and Supplementary Fig. 21). This evidence concerns the gene CD4 and myeloid sarcoma.